DDIT3 and diffuse large B-cell lymphoma: The result of the randomized phase 3 study of acalabrutinib + R-CHOP vs. R-CHOP alone in patients with newly diagnosed non-GCB DLBCL (ESCALDE, NCT04529772) may further address the efficacy and safety of the addition of BTKi therapy in combination with R-CHOP in patients with DEL.